US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
BHP Shares Fall as Jansen Potash Project Costs Surge 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Trump Says Anthropic No Longer Seen as National Security Threat 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
DURHAM, N.C., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Chief Executive Officer, will deliver a corporate presentation at the 8th Annual Biotech Showcase™, being held January 11-13, 2016 in San Francisco, CA.
8th Annual Biotech Showcase™
Date: Wednesday, January 13, 2016
Time: 11:30 a.m. Pacific Time
Location: Parc 55 San Francisco Union Square Hotel – Room: Mission II (4th Floor)
Links to a live audio webcast and replay of the presentation may be accessed on Heat Biologics’ website at http://ir.heatbio.com/events-presentations.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); T cell co-stimulation to further enhance patients’ immune response; and reversal of tumor-induced immune suppression. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
